Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, de Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Wu S, Markensohn J, Zhang Y, Loboda A, Vajdi A, Perini RF, Burgents J, Powles T

Open source

DOI: 10.1038/s41591-025-03867-5
Published: 2025 Oct
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03867-5,
  title = {Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.},
  author = {Rini BI and Plimack ER and Stus V and Gafanov R and Waddell T and Nosov D and Pouliot F and Alekseev B and Soulières D and Melichar B and Vynnychenko I and de Azevedo SJ and Borchiellini D and McDermott RS and Bedke J and Tamada S and Wu S and Markensohn J and Zhang Y and Loboda A and Vajdi A and Perini RF and Burgents J and Powles T},
  year = {2025},
  journal = {Nature medicine},
  doi = {10.1038/s41591-025-03867-5},
  url = {https://doi.org/10.1038/s41591-025-03867-5}
}

RIS

TY  - JOUR
TI  - Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
AU  - Rini BI
AU  - Plimack ER
AU  - Stus V
AU  - Gafanov R
AU  - Waddell T
AU  - Nosov D
AU  - Pouliot F
AU  - Alekseev B
AU  - Soulières D
AU  - Melichar B
AU  - Vynnychenko I
AU  - de Azevedo SJ
AU  - Borchiellini D
AU  - McDermott RS
AU  - Bedke J
AU  - Tamada S
AU  - Wu S
AU  - Markensohn J
AU  - Zhang Y
AU  - Loboda A
AU  - Vajdi A
AU  - Perini RF
AU  - Burgents J
AU  - Powles T
PY  - 2025
JO  - Nature medicine
DO  - 10.1038/s41591-025-03867-5
UR  - https://doi.org/10.1038/s41591-025-03867-5
ER  -

APA

BI, R., ER, P., V, S., R, G., T, W., D, N., F, P., B, A., D, S., B, M., I, V., SJ, D. A., D, B., RS, M., J, B., S, T., S, W., J, M., Y, Z., A, L., A, V., RF, P., J, B., & T, P. (2025). Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.. Nature medicine. https://doi.org/10.1038/s41591-025-03867-5

Source records

pubmed · retrieved 2026-09-26T12:55:05.597Z
europe-pmc · retrieved 2026-09-26T12:55:05.597Z